Did You Work as an Amazon Delivery Driver for a Delivery Service Partner?

A class action complaint has been filed against Amazon.com, Inc., Amazon.com Services, LLC, and Amazon Logistics, Inc. (collectively, “Amazon”) on behalf of all persons who worked as Delivery Service Partner (“DSP”) drivers for Amazon in the United States at any point from June 1, 2018 through the present (the “Class Period”).

The case, Davis v. Amazon.com, Inc., et al., Case No. 3:26-cv-09948, was filed on September 7, 2026, in the U.S. District Court for the Northern District of California. The complaint alleges violations of Sections 1 and 2 of the Sherman Act and, on behalf of a California subclass, California’s Cartwright Act and Unfair Competition Law.

If you worked as an Amazon DSP driver at any time since June 1, 2018, contact Kehoe Law Firm to learn more about the allegations and your potential rights.

Amazon DSP Driver Wage and Competition Allegations

The complaint alleges that Amazon has “orchestrated a deliberate and unlawful scheme to suppress the wages of hundreds of thousands of workers across the United States” through its DSP program. It alleges that Amazon abuses its purchase power, or monopsony power, in the labor market for DSP drivers, resulting in lower wages and worse working conditions.

According to the complaint, Amazon’s alleged strategy has two core components: (1) blocking DSP drivers from unionizing, and (2) preventing DSPs from competing with one another for drivers.

• Control over DSPs and drivers: The complaint alleges Amazon maintains near-absolute control over DSPs and their drivers through contractual terms, Program Policies, the Operations Manual, business coaches, hiring and training systems, route assignments, performance goals, ratings, and other infrastructure.
• Sub-competitive wages and working conditions: The complaint alleges DSP drivers’ wages have been artificially constrained below competitive levels and that Amazon’s anticompetitive conduct has allowed it to subject DSP drivers to sub-competitive working conditions and invasive surveillance.
• Union suppression: The complaint alleges Amazon uses anticompetitive tactics to prevent DSP-driver unionization, including contractual restrictions, surveillance, threats and intimidation, termination of relationships with DSPs, and adverse action against drivers.
• No-poach restraints and worker mobility: The complaint alleges Amazon has limited DSPs’ ability to recruit drivers from other DSPs through a no-poach policy and practice, reducing inter-DSP competition for drivers and suppressing wages and other forms of compensation while worsening working conditions.
• Limited alternatives: The complaint alleges DSPs lack reasonable alternative customers and DSP drivers have no reasonable alternatives to their existing jobs.

Who Is Included in the Proposed Class?

The complaint defines the proposed National Class as “All persons who worked as DSP drivers in the United States at any point from June 1, 2018 through the present.” It also proposes a Regional Subclass consisting of class members who worked as DSP drivers in a particular region during the Class Period.

Claims and Relief Sought

The complaint alleges that Amazon violated federal antitrust laws by monopsonizing the DSP Drivers Market and restricting competition among DSPs for drivers, including through an alleged no-poach agreement. It also asserts claims under California antitrust and unfair competition laws.

The plaintiff seeks class certification, injunctive and other relief, and damages, including treble damages.

Amazon DSP Drivers: Contact Kehoe Law Firm

If you worked as a Delivery Service Partner (“DSP”) driver for Amazon since June 1, 2018, contact Kehoe Law Firm to learn more about the allegations and your potential rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

A securities class action has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and certain senior officers on behalf of persons and entities who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).

The action, Holtzman v. Beta Bionics, Inc., et al., Case No. 2:26-cv-09999, was filed on September 4, 2026 in the U.S. District Court for the Central District of California and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you acquired Beta Bionics common stock during the Class Period and suffered a financial loss, contact Kehoe Law Firm to discuss your legal rights without cost or obligation.

What Does the Beta Bionics Securities Class Action Allege?

The complaint alleges that, throughout the Class Period, Defendants repeatedly assured investors that the FDA’s regulatory concerns expressed in the Form 483 related only to a minor difference in regulatory interpretation, not the underlying safety of their flagship iLet device, and that all back-filed reports were entirely benign.

The complaint further alleges that Defendants continued to misleadingly reassure investors and deny any fundamental concerns with iLet as more information emerged showing the back-filed complaints were less benign than previously reported, and, thus, that the FDA’s objections went to the heart of iLet’s safety. The complaint alleges that these statements were false and misleading because:

• The FDA had raised serious issues concerning iLet itself, including allegations that the device was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events;
• The Form 483 identified more than 18,000 unreported complaints from iLet users, including numerous allegedly life-threatening hypoglycemic events that the Company had failed to investigate or report to the FDA;
• Hundreds of complaints allegedly involved life-threatening safety events requiring hospitalization, contrary to defendants’ statements characterizing the back-filed complaints as benign or not requiring medical intervention; and
• The complaint alleges that defendants failed to accurately describe the scope and severity of the FDA’s observations, which made remediation much more complex and extensive than defendants indicated to investors.

The Corrective Disclosures and BBNX Stock Declines

The complaint alleges that the truth about defendants’ fraud was revealed through corrective disclosures made on and between January 8, 2026 and February 24, 2026.

According to the complaint, Beta Bionics common stock fell from $31.99 per share to $20.14 per share on January 9, 2026, a 37% decline. Following the Company’s January 30, 2026 Form 8-K disclosure that it had received an FDA warning letter connected to the earlier Form 483, the stock declined from $14.79 per share to $13.83 per share.

Beta Bionics Investors: Contact Kehoe Law Firm

Investors who purchased or otherwise acquired Beta Bionics common stock during the Class Period and suffered financial losses are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to discuss their legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

Lead Plaintiff Deadline: November 3, 2026. Investors who wish to seek appointment as lead plaintiff must do so by November 3, 2026. Investors do not need to seek appointment as lead plaintiff to remain potential members of the proposed class or to be eligible to share in any potential recovery.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

A securities class action has been filed against DICK’S Sporting Goods, Inc. (“Dick’s” or the “Company”) (NYSE: DKS) and certain officers and executives on behalf of persons and entities that purchased Dick’s common stock between September 8, 2025 and August 24, 2026, inclusive (the “Class Period”).

The action, Plumbers & Pipefitters Local Union #295 Pension Fund v. DICK’S Sporting Goods, Inc., et al., Case No. 2:26-cv-01860, was filed on September 4, 2026 in the U.S. District Court for the Western District of Pennsylvania and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you purchased Dick’s common stock during the Class Period and suffered a financial loss, contact Kehoe Law Firm to discuss your legal rights without cost or obligation.

What Does the Dick’s Sporting Goods Securities Class Action Allege?

The complaint alleges that Defendants misled investors regarding the Company’s acquisition of Foot Locker, Inc. (“Foot Locker”), touting the acquisition as a strategic opportunity to drive growth and profitability while assuring investors that Foot Locker’s longstanding inventory and promotional challenges had been resolved.

Specifically, the complaint alleges that Defendants failed to disclose that:

• Dick’s cleanup efforts concerning Foot Locker’s inventory were not complete, and, in fact, Foot Locker remained saddled with unproductive and stagnant legacy footwear;
• Foot Locker heavily relied on legacy footwear products that were particularly vulnerable to intensifying promotional pressures across the athletic footwear industry;
• In turn, Dick’s was significantly exposed to an industry-wide environment of excess inventory and resulting promotional activity;
• Accordingly, Dick’s was unable to achieve the sales growth, margins, and profits it touted to investors; and
• As a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The August 25, 2026 Disclosure and DKS Stock Decline

According to the complaint, before markets opened on August 25, 2026, Dick’s issued a press release announcing its financial results for the second quarter of 2026. The Company reported adjusted earnings per share of $3.53, which fell short of analysts’ estimates of $3.76 per share, and disclosed that Foot Locker generated revenue of $1.73 billion, significantly below analysts’ expectations of $1.81 billion. Dick’s also reduced its full-year 2026 consolidated net sales guidance to a range between $21.9 billion and $22.2 billion, down from $22.1 billion to $22.4 billion, and expected Foot Locker’s proforma comparable sales to range from negative 2.0% to 0.0% for the year, down from its prior forecast of 1.5% to 3% growth.

The complaint states that Dick’s disclosed that conditions across portions of the athletic footwear and apparel marketplace had become increasingly promotional and that this environment had a more significant impact on Foot Locker due to its greater exposure to legacy footwear silhouettes and greater dependence on footwear launch and retro product. The complaint alleges that, on this news, the price of Dick’s common stock fell $55.02 per share, or approximately 30%, to close at $124.31 per share on August 25, 2026.

Dick’s Investors: Contact Kehoe Law Firm

Investors who purchased Dick’s common stock during the Class Period and suffered financial losses are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to discuss their legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

Lead Plaintiff Deadline: November 3, 2026. Investors who wish to seek appointment as lead plaintiff must do so by November 3, 2026. Investors do not need to seek appointment as lead plaintiff to remain potential members of the proposed class or to be eligible to share in any potential recovery.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

A securities class action has been filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and certain executive officers on behalf of persons and entities that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”).

The action, Patel v. Unicycive Therapeutics, Inc., et al., Case No. 3:26-cv-09559, was filed on September 3, 2026 in the U.S. District Court for the Northern District of California and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you acquired Unicycive securities during the Class Period and suffered a financial loss, contact Kehoe Law Firm to discuss your legal rights without cost or obligation.

What Does the Unicycive Therapeutics Securities Class Action Allege?

The complaint alleges that, throughout the Class Period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, the complaint alleges that defendants failed to disclose to investors:

• The Company had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices;
• As a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies;
• There was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices;
• As a result of the foregoing, the regulatory approval of oxylanthanum carbonate (“OLC”) was reasonably likely to be delayed; and
• As a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

The June 30, 2026 Disclosure and UNCY Stock Decline

According to the complaint, on June 30, 2026, before the market opened, Unicycive disclosed that the U.S. Food and Drug Administration (“FDA”) had issued a second Complete Response Letter (“CRL”) regarding the Company’s resubmitted New Drug Application (“NDA”) for OLC, identifying the “same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025.”

The complaint states that Unicycive disclosed that the FDA had not yet conducted its inspection of the third-party manufacturing vendor as part of the review of the resubmitted NDA. The Company also stated that the OLC NDA had been resubmitted based on Unicycive’s belief that the original third-party manufacturing vendor was making continued progress in resolving FDA-cited deficiencies and demonstrating inspection readiness. The FDA did not raise concerns regarding OLC’s clinical efficacy or safety data, and no additional data was requested.

The complaint alleges that, on this news, Unicycive’s stock price fell $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026, on unusually heavy trading volume.

Unicycive Therapeutics Investors: Contact Kehoe Law Firm

Investors who purchased or otherwise acquired Unicycive securities during the Class Period and suffered financial losses are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to discuss their legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

Lead Plaintiff Deadline: November 2, 2026. Investors who wish to seek appointment as lead plaintiff must do so by November 2, 2026. Investors do not need to seek appointment as lead plaintiff to remain potential members of the proposed class or to be eligible to share in any potential recovery.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]